A Breakthrough in Immunology: Novartis’ New Autoimmune Data
Novartis will deliver 27 presentations at ACR Convergence 2025, headlined by late-breaking, pivotal Phase III results from the replicate...
Enzon, Viskase Announce Amended Merger Agreement
Enzon Pharmaceuticals and Viskase Companies have amended their previously announced all-stock merger, resetting ownership so Viskase holders will own...
Supernus to Deliver Q3 2025 Financial Results on Nov. 4
Supernus Pharmaceuticals will report its third-quarter 2025 financial and business results after market close on November 4, with a...
Teva & Prestige Biopharma’s Tuznue® Licensing Deal in Europe
Teva has signed a licensing and supply agreement with Prestige Biopharma to commercialize Tuznue, a biosimilar of Herceptin (trastuzumab),...
Inotiv Announces November 2025 Investor Conference Lineup
Inotiv will hit the investor circuit in November, with management slated for one-on-one meetings at the UBS Global Healthcare...
Nurexone to Present at Cambridge’s Precision EV Forum
Nurexone Biologic will take the regulatory stage at the Precision EV Forum 2025 in Cambridge, UK, where its Director...
Rhythm Pharmaceuticals to Report Q3 2025 Financial Results
Rhythm Pharmaceuticals will report third-quarter 2025 results on November 4 and is lining up two investor discussions on November...
Cytomed Makes Cash Bid for TC Biopharm Acquisition
Cytomed Therapeutics has submitted a cash bid to acquire selected assets of TC BioPharm, which entered administration on October...
Rezolute Announces Participation in Investor Conferences
Rezolute will hit the fall investor circuit with back-to-back appearances at the Maxim Growth Summit on October 22–23, the...
Teva, Prestige BioPharma in Tuznue® Deal for Europe
Teva has signed a license and supply agreement with Prestige Biopharma to commercialize Tuznue, a biosimilar to Herceptin (trastuzumab),...